Skip to main content Skip to footer

Next generation precision medicines drive better patient outcomes

Next generation digital, clinical, and financial solutions will make them accessible

Why this matters

Tremendous advancements in our ability to harness the body’s natural defense mechanisms have placed potentially curative therapies within our reach. Outdated processes and technology may allow these opportunities to elude us. If we do not seize these opportunities, progress will stagnate, and it is imperative that we advance.

DATA

12 years

since Emily Whitehead was cured of leukemia with CAR-T

37

FDA approved cell and gene therapy products

3%

of addressable patients who can access CAR-T therapy

How Advanced Therapies are changing

Right now is the time for change

Scientists, doctors, engineers, caregivers, and others are working to make advanced therapies easier to develop and administer, and more accessible to patients.

What you can do

By baking in data sharing and interoperability to the protocol design, demonstrating the feasibility of at-scale manufacturing early in development, and accepting and planning the inherent variability in the process.

Learn more

By investing in digital capabilities to help assess the process. Leverage analytics and automation to streamline manufacturing for optimal results.

Learn more

Advocate for earlier interventions based on safety and efficacy. Evaluate new financial models to improve affordability. Look into regulatory options to expand into other medical areas, such as solid tumors and non-oncology diseases.

Learn more

By connecting centers and manufacturers, admin burdens can be reduced, costs lowered, and therapy access accelerated. By ensuring GxP and HIPAA compliance, data and IP is protected. By using modular tools, therapies are supported at every stage.

Our leader

Sanjay Srivastava, Ph.D

Managing Director – Life Sciences, Cell and Gene Lead

LinkedIn